# SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma

> **NCT07104331** · PHASE2 · RECRUITING · sponsor: **Sarcoma Alliance for Research through Collaboration** · enrollment: 41 (estimated)

## Conditions studied

- Epithelioid Hemangioendothelioma (EHE)

## Interventions

- **DRUG:** nab-Sirolimus

## Key facts

- **NCT ID:** NCT07104331
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-24
- **Primary completion:** 2029-08-30
- **Final completion:** 2029-08-30
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07104331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07104331, "SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07104331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*